U.S. FDA may nix black box warning on some menopause estrogen treatments

If a panel convened by the U.S. Food and Drug Administration has its way, a health risk warning included in hormone treatments for symptoms of menopause may soon be removed.

On July 17, FDA Commissioner Martin Makary, a longtime proponent of estrogen and other menopause hormone treatments, hosted a panel of experts who oppose the so-called black box warning. Makary invited the panelists to “update us, teach us about the latest evidence, and help guide us as we think through…